Nityr is owned by Cycle Pharms Ltd.
Nityr contains Nitisinone.
Nityr has a total of 1 drug patent out of which 0 drug patents have expired.
Nityr was authorised for market use on 26 July, 2017.
Nityr is available in tablet;oral dosage forms.
Nityr can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.
The generics of Nityr are possible to be released after 05 January, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10328029||CYCLE PHARMS LTD||Pharmaceutical composition|| |
(11 years from now)
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic